Publications by authors named "Doreen Garabedian"
Previous herpes simplex virus type 2 (HSV-2) vaccines have not prevented genital herpes. Concerns have been raised about the choice of antigen, the type of antibody induced by the vaccine, and whether antibody is present in the genital tract where infection occurs. We reported results of a trial of an HSV-2 replication-defective vaccine, HSV529, that induced serum neutralizing antibody responses in 78% of HSV-1-/HSV-2- vaccine recipients.
View Article and Find Full Text PDFArticle Synopsis
- Chronic active Epstein-Barr virus (CAEBV) is characterized by high levels of EBV in the blood, particularly in natural killer (NK) cells, and the presence of immature NK cells, but its underlying causes are not well understood.* -
- A study of two patients with NK cell CAEBV revealed increased phosphorylation of signaling proteins (Akt, S6, STAT1) in their NK cells, indicating abnormal signaling pathways typically associated with the disease.* -
- The use of JAK inhibitors in the lab was effective in normalizing STAT1 phosphorylation in the patients' NK cells, suggesting a potential new treatment strategy for CAEBV.*
A Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of a Replication-Defective Herpes Simplex Virus (HSV) Type 2 Vaccine, HSV529, in Adults With or Without HSV Infection.
J Infect Dis
August 2019
Background: Herpes simplex virus 2 (HSV2) causes genital herpes in >400 million persons worldwide.
Methods: We conducted a randomized, double-blinded, placebo-controlled trial of a replication-defective HSV2 vaccine, HSV529. Twenty adults were enrolled in each of 3 serogroups of individuals: those negative for both HSV1 and HSV2 (HSV1-/HSV2-), those positive or negative for HSV1 and positive for HSV2 (HSV1±/HSV2+), and those positive for HSV1 and negative for HSV2 (HSV1+/HSV2-).